The investigation into human butyrylcholinesterase (hBChE) inhibitors as therapeutic agents for Alzheimer's disease (AD) holds significant promise, addressing both symptomatic relief and disease progression. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.